We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Innovation Pharmaceuticals Inc (CE) | USOTC:IPIX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0011 | 73.33% | 0.0026 | 0.0026 | 0.0015 | 0.0015 | 15,100 | 19:58:19 |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2017
CELLCEUTIX CORPORATION |
(Exact name of registrant as specified in its charter) |
Nevada |
|
000-52321 |
|
30-0565645 |
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
100 Cummings Center, Suite 151-B
Beverly, MA 01915
( Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (978) 921-4125
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02 Results of Operations and Financial Condition.
On March 27, 2017 Cellceutix Corporation issued a press release titled “ Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment”
A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 2.02, including the accompanying press release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
|
2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELLCEUTIX CORPORATION | |||
Dated: March 27, 2017 | By: | /s/ Leo Ehrlich | |
|
Name: |
Leo Ehrlich | |
Title: | Chief Executive Officer |
3 |
|
Exhibit Index
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release dated March 27, 2017. |
4 |
1 Year Innovation Pharmaceuticals (CE) Chart |
1 Month Innovation Pharmaceuticals (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions